A $10-million grant from the National Institutes of Health (NIH) will help fund the first U.S.-based clinical trial of Synchron’s Stentrode, a wireless brain device, implanted without open brain surgery, that transmits signals from the brain directly to a computer. The COMMAND trial will evaluate whether the device…
News
The Adira Foundation is inviting people with neurodegenerative diseases and their caregivers to join a grant proposal review committee. A nonprofit foundation, its mission is to unite people affected by some of most common neurodegenerative diseases — namely, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer’s disease, Huntington’s disease, and…
Bringing artificial intelligence (AI) to the development of small molecule therapies for amyotrophic lateral sclerosis (ALS) and other neurological diseases is the goal of a business partnership in Asia. The newly signed agreement is between Insilico Medicine, an AI-driven drug discovery company based in Hong Kong, and 4B Technologies of Suzhou,…
Dropping the levels of microRNA-218 (miR-218) — a small molecule that regulates the activity of other genes — below a certain threshold leads to severe motor neuron damage, paralysis, and death in a mouse model of amyotrophic lateral sclerosis (ALS), a study shows. The findings, combined with the fact that…
The National Organization for Rare Disorders, known as NORD, was named an official charity partner of the 2021 TCS New York City Marathon, which will be held Nov. 7 both in-person and online. “Supporting charitable causes and organizations are a long-standing tradition of the TCS New York City…
A national agency in Norway has given AB Science the go-ahead to resume enrollment in AB19001, a Phase 3 clinical trial investigating the safety and efficacy of the company’s investigational oral therapy masitinib in people with amyotrophic lateral sclerosis (ALS). AB had voluntarily suspended recruitment and treatment…
Mast cells, a type of immune cell, infiltrate the spinal cord of amyotrophic lateral sclerosis (ALS) patients and rodent models of the disease, exhibiting pro-inflammatory features that are likely involved in motor neuron and microvasculature damage, a study suggests. Notably, treating these mice models with masitinib — an experimental oral…
Eledon Pharmaceuticals announced that its Phase 2 study of AT-1501 in people with amyotrophic lateral sclerosis (ALS) should be fully enrolled by year’s end. Top-line trial results are expected between April and September 2022. “Enrollment in our ALS study is progressing well and we anticipate completing enrollment in…
I AM ALS, a nonprofit dedicated to helping people affected by amyotrophic lateral sclerosis (ALS), is expanding its efforts in scientific research and public policy. The organization’s new Science and Policy program will include three key focuses, according to a press release emailed to ALS News Today.
The National Alliance for Caregiving, in partnership with Global Genes, has issued a free guidebook, available online, that offers resources and support for caregivers of children with rare diseases. “The Circle of Care Guidebook for Caregivers of Children With Rare and/or Serious Illnesses” was designed…
Recent Posts
- A dream takes me back to a time before life with ALS
- ALS ONE joining ALS Network to strengthen research, services
- Rollator revamp needed because design matters for living well with ALS
- Study probes high ALS risk in elite athletes and other ‘champions’
- First ALS patient dosed in study of experimental gene therapy VTx-002